International network for natural sciences – research journal
  • mendeley icon
  • linkedin icon
  • google plus icon
  • twitter icon
  • google scholar icon
  • facebook icon

Factors linked to sustained virological response rates during antiviral therapy in chronic hepatitis-C patients from slums of Islamabad

By: Asad Zia, Muhammad Ali, Sohail Akhtar, Muhammad Zia, Abida Raza

Key Words: Hepatitis C virus, IL 28B polymorphism, Ribavirin, Interferon, Sustain virological response rate

Int. J. Biosci. 10(4), 354-362, April 2017.

DOI: http://dx.doi.org/10.12692/ijb/10.4.354-362

Abstract

Human genetic and viral factors are the key factors correlated with treatment response and spontaneous clearness of HCV infections. In the current study, we investigate the possible correlation of HCV-3a genotype, viral load, host age, gender and IL28B (rs12979860) polymorphism with interferon plus ribavirin treatment. Sixty seven chronic HCV patients were selected for the current study to assess the dependence of treatment out-comes in patients undergoing combination therapy (IFN plus RBV). Patients with age ≥16 years, both gender males and females, having no co-infection with HBV or HIV, no liver complications e.g. (cirrhosis, fibrosis, and hepatocellular carcinoma) were included in the study. Twenty HCV infected patients were excluded from the study who did not qualify the criteria. Of the remaining sixty seven, 37 (55.22%) were female and 30 (44.77%) were male. For HCV genotyping, from the serum viral RNA was extracted and for host genetic factor IL28B (rs12979860) polymorphism was assessed, for this purpose, whole blood was used for extraction of genomic DNA, PCR amplification of 694 bp of IL28B (rs12979860) was carried out followed by IL28B typing by restriction fragment length polymorphism. We found dominated HCV genotype (HCV-3a) 62.68% (42/67) in slums of Islamabad followed by HCV-1a 26.86% (18/67) and 10.44% (7/67) were infected with untypable. For IL28B we found three types of polymorphism in rs12979860, the most prevalent polymorphism among the present study patricians is CC (81.57%) followed by CT (55.55%) while CT (9%) were rarely found. The SVR was significantly higher in patients with CC polymorphism at IL28B (rs12979860) (p= 0.000)and is not effected by other host factors such as gender (p= 0.035), age (p= 0.352).

| Views 33 |

Factors linked to sustained virological response rates during antiviral therapy in chronic hepatitis-C patients from slums of Islamabad

Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR. 2011. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 53(1), 336-345.

Akbar H, Idrees M, Manzoor S, Ur Rehman I, Butt S, Yousaf M, Rafique S, Awan Z, Khubaib B, Akram M. 2009. Hepatitis C virus infection: A review of the current and future aspects and concerns in Pakistan. Journal of General and Molecular Virology 1(2), 012-018.

Ali M, Afzal S, Zia A, Hassan A, Khalil AT, Ovais M, Shinwari ZK, Idrees M. 2016. A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges. Medicine 95(50), e5327.

Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H. 2014. Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Journal of gastroenterology 49(7),1152-1162.

Aslam K. 2016. Pakistan: “When they are diagnosed with hepatitis C, patients think they will die”. Médecins Sans Frontières.

Asselah T, De Muynck S, Broet P, Masliah-Planchon J, Blanluet M, Bieche I, Lapalus M, Martinot-Peignoux M, Lada O, Estrabaud E. 2011. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis c; wiley-blackwell commerce place, 350 main st, malden 02148, ma USA. p 868A-868A.

Asselah T, De Muynck S, Broët P, Masliah-Planchon J, Blanluet M, Bièche I, Lapalus M, Martinot-Peignoux M, Lada O, Estrabaud E. 2012. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. Journal of hepatology 56(3), 527-532.

Aziz H, Gil ML, Waheed Y, Adeeb U, Raza A, Bilal I, Athar MA. 2011. Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan. Infection, Genetics and Evolution 11(3), 640-645.

Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML. 2015a. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 30, 91-97.

Aziz H, Raza A, Ali K, Khattak JZK, Irfan J, Gill ML. 2015b. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy. International Journal of Infectious Diseases 30, 91-97.

Aziz H, Raza A, Waheed Y, Gill U, Gill ML. 2012. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients. International Journal of Infectious Diseases 16(8), e597-e602.

Bota S, Sporea I, Şirli R, Neghină AM, Popescu A, Străin M. 2013. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis. Clinical drug investigation 33(5), 325-331.

Cieśla A, Bociąga-Jasik M, Sobczyk-Krupiarz I, Głowacki MK, Owczarek D, Cibor D, Sanak M, Mach T. 2012. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C. World Journal of Gastroenterology: WJG 18(35), 4892.

Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, Parham P, Walker CM. 1999. Analysis of a successful immune response against hepatitis C virus. Immunity 10(4), 439-449.

Dalgard O, Bjøro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H. 2004. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40(6), 1260-1265.

De Nicola S, Aghemo A, Grazia Rumi M, Galmozzi E, Valenti L, Soffredini R, De Francesco R, Prati GM, D’Ambrosio R, Cheroni C. 2012. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 55(2), 336-342.

El-Zanaty F, Way A. 2009. Egypt Demographic and Health Survey, 2008. Ministry of Health, El-Zanaty and Associates, and Macro International, Cairo Egypt.

Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Anwar W, Sallam I. 2000. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. The Lancet 355(9207), 887-891.

Fried MW. 2002. Side effects of therapy of hepatitis C and their management. Hepatology 36(S1).

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401.

Idrees M. 2008. Development of an improved genotyping assay for the detection of hepatitis C virus genotypes and subtypes in Pakistan. Journal of virological methods 150(1), 50-56.

Idrees M, Riazuddin S. 2008. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC infectious diseases 8(1), 1.

Kau A, Vermehren J, Sarrazin C. 2008. Treatment predictors of a sustained virologic response in hepatitis B and C. Journal of hepatology 49(4), 634-651.

Khairy M, Fouad R, Mabrouk M, El-Akel W, Awad AB, Salama R, Elnegouly M, Shaker O. 2013. The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysis. Hepatitis monthly 13(7).

Khan T, Qazi J. 2013. Hurdles to the global antipolio campaign in Pakistan: an outline of the current status and future prospects to achieve a polio free world. Journal of epidemiology and community health 67(8), 696-702.

Lazarevic I, Djordjevic J, Cupic M, Karalic D, Delic D, Svirtlih N, Simonovic J, Svorcan P, Milic N, Jovanovic T. 2013. The influence of single and combined IL28B polymorphisms on response to treatment of chronic hepatitis C. Journal of Clinical Virology 58(1), 254-257.

Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D. 2010. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 139(3), 821-827. e821.

McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, Tillmann HL, Muir AJ, McHutchison JG. 2010. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138(7), 2307-2314.

McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine 361(6), 580-593.

Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. 2015. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61(1), 77-87.

Moghaddam A, Melum E, Reinton N, RingLarsen H, Verbaan H, Bjøro K, Dalgard O. 2011. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 53(3), 746-754.

Moreira S, Garcia RF, Gutberlet A, Bertol BC, Ferreira LE, Pinho Mde S, de Franca PH. 2012. A straightforward genotyping of the relevant IL28B SNPs for the prediction of hepatitis C treatment outcome. Journal of virological methods 184(1-2), 93-97.

Ohno O, Mizokami M, Wu R-R, Saleh MG, Ohba K-i, Orito E, Mukaide M, Williams R, Lau J. 1997. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. Journal of clinical microbiology 35(1), 201-207.

Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J. 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138(4), 1338-1345. e1337.

Rehermann B, Nascimbeni M. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Reviews Immunology 5(3), 215-229.

Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C, Herrmann E, Lötsch J, Berg T. 2011. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. Journal of hepatology 54(3), 415-421.

Shaala AY, Morsi MG, Harfoush RAH, ElKhouly EH, Ahmed MAR, Roshdy MN. 2015. Role of IL-28B polymorphisms in virologic response to combined pegylated interferon and ribavirin therapy in genotype 4 chronic HCV infected patients with and without cirrhosis. Alexandria Journal of Medicine 51(3), 231-239.

Shepard CW, Finelli L, Alter MJ. 2005. Global epidemiology of hepatitis C virus infection. The Lancet infectious diseases 5(9), 558-567.

Shinwari ZK, Khalil AT, Nasim A. 2014. Natural or deliberate outbreak in Pakistan: how to prevent or detect and trace its origin: biosecurity, surveillance, forensics. Archivum immunologiae et therapiae experimentalis 62(4), 263-275.

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E. 2009. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nature genetics 41(10), 1100-1104.

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S. 2009. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature genetics 41(10), 1105-1109.

Wohnsland A, Hofmann WP, Sarrazin C. 2007. Viral determinants of resistance to treatment in patients with hepatitis C. Clinical microbiology reviews 20(1), 23-38.

Zeuzem S, Soriano V, Asselah T, Bronowicki J-P, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK. 2013. Faldaprevir and deleobuvir for HCV genotype 1 infection. New England Journal of Medicine 369(7), 630-639.

Asad Zia, Muhammad Ali, Sohail Akhtar, Muhammad Zia, Abida Raza.
Factors linked to sustained virological response rates during antiviral therapy in chronic hepatitis-C patients from slums of Islamabad.
Int. J. Biosci. 10(4), 354-362, April 2017.
http://www.innspub.net/ijb/factors-linked-sustained-virological-response-rates-antiviral-therapy-chronic-hepatitis-c-patients-slums-islamabad/
Copyright © 2017
By Authors and International Network for
Natural Sciences (INNSPUB)
http://innspub.net
brand
innspub logo
english language editing
  • CALL FOR PAPERS
    CALL FOR PAPERS
    Publish Your Article
  • CALL FOR PAPERS
    CALL FOR PAPERS
    Submit Your Article
INNSPUB on FB
Email Update